July 17, 2024 – Pfizer Inc. introduced that the corporate is starting the method to establish a successor to Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Analysis & Growth, who can be leaving the corporate after a stellar profession spanning greater than 15 years. This course of is anticipated to take a number of months, seemingly into early subsequent yr. Pfizer will provoke an exterior seek for a brand new Chief Scientific Officer, and Dr. Dolsten will help on this search and can proceed in his present position till his successor is appointed and the required transition is full.

Throughout his tenure at Pfizer, the corporate has obtained greater than 35 drug and vaccine approvals up to now, greater than half of which had been novel molecular entities. These embody merchandise starting from therapies for inflammatory illnesses, heart problems, stroke prevention, hemophilia and most cancers, to Pfizer’s vaccines for RSV, pneumococcal and meningococcal illnesses, together with his most notable achievements being the event and subsequent approval of the corporate’s COVID-19 vaccine and oral therapeutic.

Discover out extra